PolyPid

PYPD · NASDAQ · Healthcare / Biotechnology

6.26USD-0.14 (-2.19%)

Price History

Full chart

Market Stats

Previous Close6.40

Open6.58

Day Range6.03 – 6.58

52-Week Range3.06 – 5.73

Volume193.16K

Market Cap107.86M

P/E (TTM)0.00

Forward P/E0.00

EPS-1.33

Dividend Yield0.00%

Beta1.42

50-Day Avg4.87

200-Day Avg4.61

About

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMs. Dikla Czaczkes Akselbrad
Employees69
Headquarters18 Hasivim Street, Petah Tikva, Israel, 4959376, USA
Websitehttps://www.polypid.com

Leadership

Ms. Dikla Czaczkes AkselbradCEO & Director · b. 1973
Mr. Jonny MissulawinChief Financial Officer · b. 1987
Ms. Dalit HazanDeputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs · b. 1972
Mr. Ori WarshavskyChief Operating Officer - US · b. 1979
Ms. Maria RubinExecutive Vice President of Operations
Mr. Tal VilnaiGeneral Counsel & Corporate Secretary
Ms. Rivi Lev-ariVice President of Human Resource
Dr. Jean-Marc Hagai Pharm.D.Chief Commercial Officer
Dr. Nurit Tweezer-Zaks M.B.A., M.D.Chief Medical Officer · b. 1967

Financials

Income Statement

Currency: USD	2012-12-31	2013-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	-	-	0	0	0	0	0	0	0	0	0	0
Cost of Revenue	-	-	108.00K	127.00K	205.00K	411.00K	947.00K	1.01M	1.12M	1.72M	1.82M	1.62M	-
Gross Profit	-	-	-108.00K	-127.00K	-205.00K	-411.00K	-947.00K	-1.01M	-1.12M	-1.72M	-1.82M	-1.62M	-
Operating Expense	-	-	11.17M	10.13M	13.60M	17.95M	17.61M	25.26M	41.76M	37.17M	21.05M	26.41M	-
Operating Income	-1.79M	-3.58M	-11.28M	-10.26M	-13.80M	-18.36M	-18.56M	-26.27M	-42.88M	-38.89M	-22.87M	-28.03M	-32.97M
EBITDA	-1.73M	-3.51M	-7.95M	-10.13M	-13.60M	-42.15M	-5.94M	-25.26M	-41.76M	-37.17M	-20.26M	-25.83M	-31.86M
Net Income	-1.79M	-3.88M	-8.22M	-11.39M	-54.49M	5.92M	-6.91M	-35.32M	-40.71M	-39.52M	-23.86M	-29.02M	-34.17M
R&D	1.38M	2.64M	5.63M	7.71M	9.74M	12.55M	14.08M	16.95M	30.42M	27.99M	16.15M	22.81M	23.81M
Interest Expense	0	0	1.69M	108.00K	16.00K	42.00K	15.00K	17.00K	87.14M	1.02M	1.71M	1.52M	685.00K

Balance Sheet

Currency: USD	2012-12-31	2013-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.55M	1.96M	2.48M	19.24M	22.98M	14.48M	33.77M	75.85M	44.23M	25.97M	15.37M	25.22M	22.31M
Total Liabilities	6.10M	10.02M	2.71M	53.20M	111.63M	96.19M	2.83M	3.07M	8.28M	20.14M	17.47M	17.54M	11.33M
Total Equity	-4.55M	-8.06M	-231.00K	-33.96M	-88.65M	-81.71M	30.93M	72.78M	35.96M	5.83M	-2.10M	7.68M	10.97M
Cash	977.00K	1.26M	1.68M	10.22M	3.91M	7.33M	3.94M	4.32M	9.82M	8.55M	5.61M	15.64M	6.40M
Total Debt	-	-	193.00K	-	-	-	-	-	-	13.73M	11.78M	9.62M	2.80M
Net Debt	-977.00K	-1.26M	-1.49M	-10.22M	-3.91M	-7.33M	-3.94M	-4.32M	-9.82M	5.18M	6.17M	-6.02M	-3.61M

Cash Flow

Currency: USD	2012-12-31	2013-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.86M	-2.52M	-6.57M	-9.73M	-12.31M	-16.68M	-17.36M	-21.60M	-32.39M	-34.32M	-17.24M	-21.96M	-27.88M
Investing Cash Flow	-145.00K	-48.00K	-102.00K	-8.07M	-8.38M	10.96M	-23.56M	-40.77M	36.90M	16.57M	3.80M	-330.00K	-
Financing Cash Flow	2.58M	2.92M	6.19M	26.34M	14.38M	9.39M	37.65M	62.77M	1.03M	16.43M	9.98M	32.42M	25.37M
Capital Expenditure	145.00K	48.00K	113.00K	539.00K	1.88M	3.07M	879.00K	1.18M	2.99M	1.77M	196.00K	76.00K	210.00K
Free Cash Flow	-2.00M	-2.57M	-6.69M	-10.27M	-14.20M	-19.75M	-18.24M	-22.77M	-35.38M	-36.08M	-17.43M	-22.04M	-28.09M
FCF to OCF	107.81%	101.91%	101.72%	105.54%	115.30%	118.43%	105.06%	105.45%	109.24%	105.15%	101.14%	100.35%	100.75%

Earnings

Report Date	Dec 20, 2017	Mar 14, 2018	Jun 29, 2020	Aug 19, 2020	Nov 11, 2020	Feb 10, 2021	May 12, 2021	Aug 11, 2021	Nov 10, 2021	Feb 9, 2022	May 11, 2022	Aug 10, 2022	Nov 9, 2022	Feb 8, 2023	May 10, 2023	Aug 9, 2023	Nov 8, 2023	Feb 14, 2024	May 8, 2024	Aug 14, 2024	Nov 13, 2024	Feb 12, 2025	May 14, 2025	Aug 13, 2025	Nov 12, 2025	Feb 11, 2026	May 13, 2026	Aug 12, 2026	Nov 11, 2026
EPS Estimate	0.00	0.00	-12.60	-6.90	-12.20	-15.23	-15.00	-15.75	-18.83	-16.64	-18.92	-20.10	-16.22	-12.36	-4.80	-13.32	-4.43	-4.29	-1.41	-1.30	-1.00	-0.88	-0.82	-0.55	-0.52	-0.33	-0.43	-0.34	0.25
EPS Actual	-0.86	-3.23	-0.33	-191.10	-10.50	-12.30	-14.10	-16.80	-15.90	-21.30	-18.90	-18.30	-14.40	-9.60	-8.40	-10.80	-3.40	-3.84	-1.37	-1.25	-1.22	-1.07	-0.70	-0.78	-0.37	-0.41	-0.35	-0.35	-
Surprise	-	-	97.42%	-2669.57%	13.93%	19.24%	6.00%	-6.67%	15.56%	-28.00%	0.11%	8.96%	11.22%	22.33%	-75.00%	18.92%	23.25%	10.49%	2.84%	3.85%	-22.00%	-21.59%	14.63%	-41.82%	28.85%	-24.24%	18.60%	-2.94%	-
Timing	-	-	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap107.86M

Enterprise Value102.05M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book19.87

EPS-1.33

Book Value0.265

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-30.12M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-243.59%

Return on Assets-74.63%

Shares Outstanding20.31M

Shares Float12.16M

Beta1.42

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 4 analystsTarget 11.75

Strong Buy
1
Buy
3

Ownership Breakdown

Institutions: 34.55%
Insiders: 17.79%
Retail / Other: 47.66%

Top Institutional Holders

AIGH Capital Management, LLC
1.50M7.41%
Rosalind Advisors, Inc.
597.93K2.94%
Dafna Capital Management LLC
207.90K1.02%
Morgan Stanley - Brokerage Accounts
176.89K0.87%
J. Goldman & Co LP
149.50K0.74%
ADAR1 Capital Management LLC
103.95K0.51%
Symmetry Peak Management LLC
100.88K0.50%
Quadrature Capital Limited
70.94K0.35%
Connective Capital Management LLC
67.60K0.33%
Citadel Advisors Llc
42.28K0.21%
Lumbard Investment Counseling LLC
38.20K0.19%
XTX Topco Ltd
29.46K0.15%
Jane Street Group LLC
21.64K0.11%
Renaissance Technologies Corp
18.60K0.09%
AXQ CAPITAL LP
17.10K0.08%
National Asset Management Inc
15.13K0.07%
BNP Paribas Arbitrage, SA
9.18K0.05%
Steward Partners Investment Advisory, LLC
7.35K0.04%

Top Fund Holders

Fidelity Nasdaq Composite Index
16.16K0.08%
LUX IM Global Medtech HX
9.90K0.05%

Stock Splits

Sep 21, 20231:30